一项关于氟伏沙明治疗合并抑郁症的惊恐障碍的开放性试验。
An open trial of fluvoxamine therapy for panic disorder complicated by depression.
作者信息
Spiegel D A, Saeed S A, Bruce T J
机构信息
Department of Psychiatry and Behavioral Medicine, University of Illinois College of Medicine at Peoria, USA.
出版信息
J Clin Psychiatry. 1996;57 Suppl 8:37-40; discussion 40-1.
BACKGROUND
The efficacy of fluvoxamine in the treatment of panic disorder complicated by depression was investigated in an 8-week, single-group, open-label, flexible-dose trial.
METHOD
Seventeen patients having a principal diagnosis of panic disorder and scoring 16 or more on the 17-item Hamilton Rating Scale for Depression were treated with fluvoxamine at a mean final dose of 213 mg/ day. Outcome was assessed on measures of panic attacks, general and anticipatory anxiety, agoraphobic avoidance, depression, disability, and fear of anxiety symptoms.
RESULTS
Subjects improved on all measures except agoraphobic avoidance. Thirteen either chose to remain on fluvoxamine treatment after the study ended or resumed taking it after a brief period without medication or on another medication.
CONCLUSION
Fluvoxamine appears to be effective in this population.
背景
在一项为期8周的单组、开放标签、灵活剂量试验中，研究了氟伏沙明治疗合并抑郁症的惊恐障碍的疗效。
方法
17例主要诊断为惊恐障碍且在17项汉密尔顿抑郁评定量表上得分16分或更高的患者接受氟伏沙明治疗，平均最终剂量为213毫克/天。通过惊恐发作、一般和预期焦虑、广场恐怖回避、抑郁、残疾以及对焦虑症状的恐惧等指标评估疗效。
结果
除广场恐怖回避外，所有指标均有改善。13名受试者在研究结束后选择继续接受氟伏沙明治疗，或在短暂停药或换用其他药物后又重新开始服用。
结论
氟伏沙明似乎对该人群有效。
Zotero 插件